Jung-Joon (John) Min / M.D.,Ph.D.
· Position : Professor and Chair, Department of Nuclear Medicine, Chonnam National University Medical School & Hwasun Hospital
· Interesting field : Molecular Imaging, Theranostics, Nuclear Oncology, Bacterio Therapy
- 2001 – 2004: Postdoctoral Fellow, Crump Institute for Molecular Imaging, UCLA David Geffen School of Medicine
- 2000 – 2001: Clinical Fellow, Seould National University Hospital
- 1996 – 2000: Residency, Dept. Nuclear Medicine, Chonnam National University Hospital
- 1998 – 2002: Ph.D., Chonnam National University
- 1985 – 1991: M.D., Chonnam National University Medical School
- 2004 – present: Professor, Chonnam National University Medical School
- 2006 – present: Director of Dept. Nuclear Medicine, Chonnam Natonal University Hwasun Hospital
- 2015 – present: Director, Institute for Molecular Imaging and Theranostics
- 2015 – present: P.I., Pioneer Research R&D Center (Center for Radiation-induced Cancer Theranostics)
- 2004 – present: P.I., Laboratory of In Vivo Molecular Imaging
Honors and Award
- 2016 The Best Researcher Award, Radiology Webzine, Korean Institute of Radiology and Medical Science
- 2015 The Scientific Achievement Award – Korean Society of Nuclear Medicine
- 2013 Seo Bong Medical Award – Chonnam National University Medical School
- 2011 The Best Article Award – Korean Society of Nuclear Medicine
- 2008 The Best Speaker’s Award – Hengstberger Symposium of Imaging Host-Pathogen Interaction. Heidelberg.
- 2006 The Best Article Award – Chonnam National University Hospital
- 2004 The Best Poster Presentation Award –Korean Society of Nuclear Medicine
- 2000 Du Pont Award – Korean Society of Nuclear Medicine
- 1998 The Young Investigator’s Award – Korean Society of Nuclear Medicine
- 1997 The Best Poster Presentation Award –Korean Society of Nuclear Medicine
- Board Member of Program Committee, World Molecular Imaging Congress (since 2014)
- Category Chair of the Program Committee, World Molecular Imaging Conference (since 2011)
- Secretary General, Korean Society of Nuclear Medicine (2016 – present)
- Director of Education and Training, Korean Society of Nuclear Medicine (2014 – 2016)
- Director of Advertisement, Korean Society of Nuclear Medicine (2012 – 2014)
- Director of Academic Affairs, Korean Society of Nuclear Medicine (2010 – 2012)
- Director of Academic Affairs, Korean Society of Molecular Imaging (2006 – 2008, 2010 – present)
- Korean Society of Nuclear Medicine Leadership Council (2008 – present)
- Secretary, Committee of Fusion Science, Korean Society of Molecular & Cellular Biology (1/2009 – 12/2009)
- Director of Educational Affairs, Korean Society of Molecular Imaging (2008 – 2010)
- Member: American Advanced Association of Science (2014 – present), American Association of Cancer Research (2015 – present), World Molecular Imaging Society (2009 – present), Academy of Molecular Imaging (U.S.A.) (2001 – 2009), European Association of Nuclear Medicine (U.K.) (2002 - present) , Society of Nuclear Medicine and Molecular Imaigng (U.S.A.) (1999 – present), Radiological Society of North America (2016 – present), IEEE (2017 – present), Society for Molecular Imaging (U.S.A.) (2005 – 2009), Korean Society of Nuclear Medicine (1996 – present), Korean Society of Molecular Imaging (2004 – present), Korean Society of Molecular & Cellular Biology (2009 – present), Korean Society of Gene & Cell Therapy (2010 – present), Optic Society of Korea (2004 - present), Korean Medical Association (1991 – present)
- Lim D et al. Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium. Oncotarget 2017 Jun 6;8(23):37550-37560.
- Yun MS et al. A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors. Theranostics 2017 Jun 25;7(10):2620-2633.
- Zheng JH et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Science Translational Medicine 2017 Feb 8;9(376).
- Park SH et al. RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy. Theranostics 2016; 6(10):1672-82.
- Kim JE et al. Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β. Theranostics 2015; 5(12): 1328-1342.
- Lee JJ et al. Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein-Drug Conjugates for Targeted Therapy. Angew Chem Int Ed Engl 2015 Oct 5;54(41):12020-4.
- Kim DY et al. Comparison of 18F-labeled Fluoroalkylphosphonium Cations with 13N-NH3 for PET Myocardial Perfusion Imaging. J Nucl Med 2015 Oct;56(10):1581-1586
- Jiang SN et al. Engineering of Bacteria for the Visualization of Targeted Delivery of a Cytolytic Anticancer Agent. Molecular Therapy 2013 Nov;21(11):1985-95.
- Le U et al. Engineering and visualization of bacteria for targeting infarcted myocardium. Molecular Therapy 2011;19(5):951-9.
- Nguyen VH et al. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Research 2010;70(1):18-23.
- Min JJ et al. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nature Protocols 2008;3(4):629-36